Last week, SentryX presented its Phase 1b clinical results at Global Spine Congress 2025 in Rio de Janeiro. Our colleague Hein Jonkman delivered a well-received presentation, providing an update on our Phase 1b trial by presenting the results of an independently verified statistical model .

The analysis, comparing outcomes from 11 treated patients to an observational cohort of 41, showed a 42% reduction in opioid use and a 49% decrease in reported pain scores at 72 hours following spine surgery. Importantly, a clinically meaningful effect size was already observed within the first 24 hours, supporting the potential to facilitate early discharge.

We’re grateful to all attendees who engaged with the data and contributed to the discussion. This milestone reflects our ongoing commitment to advancing safer, more effective pain management after spine surgery.